Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Atorvastatin calcium tablets (Lipitor)

Hypercholesterolemia Patients with primary hypercholesterolemia. Including patients with familial hypercholesterolemia (heterozygous type) or mixed hyperlipidemia (equivalent to Fredrickson classification IIA and IIB). If the efficacy of dietary treatment and other non drug treatment is not satisfactory, this product can treat the increase of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B) and triglyceride (TG) rise. In homozygous familial hypercholesterolemia patients, atorvastatin can be used in combination with other lipid-lowering therapies (such as LDL plasma dialysis) or alone (when there is no other treatment) to reduce TC and LDL-C. coronary heart disease Patients with coronary heart disease or coronary heart disease, such as diabetes mellitus, symptomatic atherosclerosis, and hypercholesterolemia or mixed dyslipidemia, are suitable for reducing the risk of non fatal myocardial infarction, reducing the risk of fatal and non fatal stroke, reducing the risk of revascularization, and reducing the risk of hospitalization due to congestive heart failure. Reduce the risk of angina pectoris. More role
App download minus 10 yuan
Common name:
Atorvastatin calcium tablets
Product No.:
A14202006561
Approval No.:
Gyzz h20051408 (inquired by the State Drug Administration)
Jianke price:
¥89.00
Product specification:
20mg*28S 10mg*7s 20mg * 7 tablets 20mg * 7 tablets * 5 boxes + 10mg * 30s 20mg * 7 tablets * 4 boxes + 0.6g * 60 Tablets 10mg * 7S * 6 boxes + 10mg * 30s
Manufacturer:
Pfizer Pharmaceuticals Limited
number        Quantity:
Add to list
Tips:
This product is a prescription drug. Please buy it with the prescription paper; Delivered by Jianke offline drugstore
 
(for assistance, please call400-086-5111
Jianke promises:
Genuine guarantee
Bank remittance / transfer online payment
  • Product introduction
  • instructions
  • Qualification certificate
  • Relevant information
Product name Atorvastatin calcium tablets (Lipitor)
Main raw materials The main component of this product is atorvastatin calcium. The chemical name is: EP, - (R ', R')] - 2 - (4-fluorophenyl) B · 6-dihydroxy-5-1-methylethyl-3-phenyl-4 - [(aniline) off] - 1-hydro-pyrrole-1-heptanate calcium trihydrate.
Main role Hypercholesterolemia Patients with primary hypercholesterolemia. Including patients with familial hypercholesterolemia (heterozygous type) or mixed hyperlipidemia (equivalent to Fredrickson classification IIA and IIB). If the efficacy of dietary treatment and other non drug treatment is not satisfactory, this product can treat the increase of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B) and triglyceride (TG) rise. In homozygous familial hypercholesterolemia patients, atorvastatin can be used in combination with other lipid-lowering therapies (such as LDL plasma dialysis) or alone (when there is no other treatment) to reduce TC and LDL-C. coronary heart disease Patients with coronary heart disease or coronary heart disease, such as diabetes mellitus, symptomatic atherosclerosis, and hypercholesterolemia or mixed dyslipidemia, are suitable for reducing the risk of non fatal myocardial infarction, reducing the risk of fatal and non fatal stroke, reducing the risk of revascularization, and reducing the risk of hospitalization due to congestive heart failure. Reduce the risk of angina pectoris.
Product specification 20mg * 7 tablets
Usage and dosage Patients should take standard low cholesterol diet control before starting treatment with this product, and maintain a reasonable diet throughout the treatment period. The dose should be adjusted individually according to the baseline level of low-density lipoprotein cholesterol, treatment objectives and treatment effects of patients. The commonly used starting dose is 10mg once a day. The dose adjustment interval should be 4 weeks or more. The maximum dose of this product is 80mg once a day. It can be taken at any time of the day and is not affected by meals. For low-risk patients with cardiovascular events, the treatment objectives are LDL-C < 4.14 mmol / L (or < 160 mg / dl) and total cholesterol < 6.62 mmol / L (or < 240 mg / dl). The treatment targets of moderate risk patients were LDL-C < 3.37 mmol / L (or < 130 mg / dl) and total cholesterol < 5.18 mmol / L (or < 220 mg / dl). The treatment targets of high-risk patients were LDL-C < 2.59 mmol / L (or < 100 mg / dl) and total cholesterol < 4.14 mmol / L (or < 160 mg / dl). The treatment targets of extremely high-risk patients were LDL-C < 2.07 mmol / L (or < 80 mg / dl) and total cholesterol < 3.11 mmol / L (or < 120 mg / dl). Excerpted from "guidelines for the prevention and treatment of dyslipidemia in Chinese adults" on pages 390-431, Volume 35, issue 5, Chinese Journal of cardiovascular disease, 2007. Treatment of primary hypercholesterolemia and mixed hyperlipidemia Most patients take atorvastatin calcium 10 mg once a day, and their blood lipid level can be controlled. Significant effect was observed within 2 weeks and 4 weeks after treatment. Long term treatment can maintain the curative effect. Treatment of heterozygous familial hypercholesterolemia The patient's initial dose was 10 mg per day. The principle of dose individualization should be followed, and the dose should be gradually adjusted to 40 mg per day every 4 weeks. If the curative effect is still not satisfactory, you can choose to adjust the dose to the maximum dose of 80 mg per day or 40 mg of this product combined with cholic acid Ao mixture. Homozygous familial hypercholesterolemia in a charity study of 64 patients, 46 of whom had corresponding LDL receptor information. LDL-C decreased by an average of 21% in these 46 patients. The dose of this product can be increased to 80 mg per day. Treatment of homozygous familial hypercholesterolemia In a charity medication study involving 64 patients, 46 of them had confirmed LDL receptor information. LDL-C decreased by an average of 21% in these 46 patients. The dose of this product can be increased to 80mg / day. For homozygous familial hypercholesterolemia patients, the recommended dose of this product is 10-80 mg per day. Atorvastatin calcium should be used as an adjuvant therapy for other lipid-lowering treatment measures (such as LDL plasma dialysis). Or when these treatment conditions are not available, this product can be used alone. Dosage in patients with renal insufficiency Kidney disease will neither affect the plasma concentration of this product nor its lipid-lowering effect, so there is no need to adjust the dose.
manufacturing enterprise Pfizer Pharmaceuticals Limited
Jianke commitment
  • Genuine guarantee, formal invoice

    Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

  • Private packaging, privacy protection

    When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

  • Efficient logistics and safe arrival

    All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

  • Three warehouses to ensure inventory

    Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Specially assigned person to manage and ensure product inventory.

[drug name] Atorvastatin calcium tablets (Lipitor)

[common name] Atorvastatin calcium tablets

[specification and model] 20mg * 7 tablets

[manufacturer] Pfizer Pharmaceuticals Limited

[drug type] Western medicine

[approval No.] Gyzz h20051408

[validity period] 36 months

[functional indications] Hypercholesterolemia Patients with primary hypercholesterolemia. Including patients with familial hypercholesterolemia (heterozygous type) or mixed hyperlipidemia (equivalent to Fredrickson classification IIA and IIB). If the efficacy of dietary treatment and other non drug treatment is not satisfactory, this product can treat the increase of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B) and triglyceride (TG) rise. In homozygous familial hypercholesterolemia patients, atorvastatin can be used in combination with other lipid-lowering therapies (such as LDL plasma dialysis) or alone (when there is no other treatment) to reduce TC and LDL-C. coronary heart disease Patients with coronary heart disease or coronary heart disease, such as diabetes mellitus, symptomatic atherosclerosis, and hypercholesterolemia or mixed dyslipidemia, are suitable for reducing the risk of non fatal myocardial infarction, reducing the risk of fatal and non fatal stroke, reducing the risk of revascularization, and reducing the risk of hospitalization due to congestive heart failure. Reduce the risk of angina pectoris.

[usage and dosage] Patients should take standard low cholesterol diet control before starting treatment with this product, and maintain a reasonable diet throughout the treatment period. The dose should be adjusted individually according to the baseline level of low-density lipoprotein cholesterol, treatment objectives and treatment effects of patients. The commonly used starting dose is 10mg once a day. The dose adjustment interval should be 4 weeks or more. The maximum dose of this product is 80mg once a day. It can be taken at any time of the day and is not affected by meals. For low-risk patients with cardiovascular events, the treatment objectives are LDL-C < 4.14 mmol / L (or < 160 mg / dl) and total cholesterol < 6.62 mmol / L (or < 240 mg / dl). The treatment targets of moderate risk patients were LDL-C < 3.37 mmol / L (or < 130 mg / dl) and total cholesterol < 5.18 mmol / L (or < 220 mg / dl). The treatment targets of high-risk patients were LDL-C < 2.59 mmol / L (or < 100 mg / dl) and total cholesterol < 4.14 mmol / L (or < 160 mg / dl). The treatment targets of extremely high-risk patients were LDL-C < 2.07 mmol / L (or < 80 mg / dl) and total cholesterol < 3.11 mmol / L (or < 120 mg / dl). Excerpted from "guidelines for the prevention and treatment of dyslipidemia in Chinese adults" on pages 390-431, Volume 35, issue 5, Chinese Journal of cardiovascular disease, 2007. Treatment of primary hypercholesterolemia and mixed hyperlipidemia Most patients take atorvastatin calcium 10 mg once a day, and their blood lipid level can be controlled. Significant effect was observed within 2 weeks and 4 weeks after treatment. Long term treatment can maintain the curative effect. Treatment of heterozygous familial hypercholesterolemia The patient's initial dose was 10 mg per day. The principle of dose individualization should be followed, and the dose should be gradually adjusted to 40 mg per day every 4 weeks. If the curative effect is still not satisfactory, you can choose to adjust the dose to the maximum dose of 80 mg per day or 40 mg of this product combined with cholic acid Ao mixture. Homozygous familial hypercholesterolemia in a charity study of 64 patients, 46 of whom had corresponding LDL receptor information. LDL-C decreased by an average of 21% in these 46 patients. The dose of this product can be increased to 80 mg per day. Treatment of homozygous familial hypercholesterolemia In a charity medication study involving 64 patients, 46 of them had confirmed LDL receptor information. LDL-C decreased by an average of 21% in these 46 patients. The dose of this product can be increased to 80mg / day. For homozygous familial hypercholesterolemia patients, the recommended dose of this product is 10-80 mg per day. Atorvastatin calcium should be used as an adjuvant therapy for other lipid-lowering treatment measures (such as LDL plasma dialysis). Or when these treatment conditions are not available, this product can be used alone. Dosage in patients with renal insufficiency Kidney disease will neither affect the plasma concentration of this product nor its lipid-lowering effect, so there is no need to adjust the dose.

[adverse reactions] 1. The most common adverse reaction of this product is gastrointestinal discomfort, and others include headache, rash, dizziness, blurred vision and taste disorder. 2. Occasionally, it can cause the reversibility of blood aminotransferase to increase. Therefore, liver function needs to be monitored. 3. Rare adverse reactions include impotence and insomnia. 4. Rare adverse reactions include myositis, myalgia and rhabdomyolysis, which are characterized by muscle pain, fatigue and fever, accompanied by elevated serum creatine phosphokinase and myoglobinuria. Rhabdomyolysis can lead to renal failure, but it is rare. This product can increase the risk of myopathy when combined with immunosuppressants, folic acid derivatives, niacin, gemfibrozil, erythromycin, etc. 5. There are reports of hepatitis, pancreatitis and allergic reactions, such as angioneuroedema. See the inner packaging instructions for details.

[precautions] l. Blood cholesterol and creatine phosphokinase should be checked regularly during medication. Blood aminotransferase may increase when using this product. People with a history of liver disease should also regularly monitor liver function test. 2. During the treatment of this product, if the increase of blood aminotransferase is up to 3 times of the normal high limit, or the blood creatine phosphokinase is significantly increased, or there are signs of myositis and pancreatitis, this product should be stopped. 3. In case of hypotension, severe acute infection, trauma, metabolic disorder, etc. when using this product, attention should be paid to the possible renal failure secondary to myolysis. 4. Reduce the dose of this product in case of renal insufficiency. 5. This product should be promoted together with the diet to facilitate absorption. 6. Diet therapy is always the primary method for the treatment of hyperlipidemia. Strengthening exercise and weight loss will be better than any form of drug treatment. See the inner packaging instructions for details. Please read the instructions carefully and follow the doctor's advice.

[taboo] 1. Active liver diseases, including unexplained liver aminotransferase, continue to rise 2. Known to be allergic to any of the ingredients in this product. 3. Pregnancy This product is prohibited for pregnant women or women of childbearing age who may be pregnant. Pregnant women may cause damage to the fetus when taking this product. In normal pregnancy, the levels of serum cholesterol and triglycerides increase, and cholesterol or cholesterol derivatives are essential substances for fetal development. Atherosclerosis is a chronic pathological process, so the discontinuation of lipid-lowering drug therapy in patients with primary hypercholesterolemia during pregnancy has little effect on the long-term outcome of atherosclerotic disease. There is a lack of sufficient controlled studies on atorvastatin in pregnant women; However, it is occasionally reported that fetal congenital abnormalities can occur when intrauterine exposure to statins. No evidence of teratogenicity of atorvastatin was observed in the reproductive studies of rats and rabbits. For women of childbearing age, only those who are highly unlikely to conceive and have been informed of potential hazards can be prescribed Lipitor. During pregnancy, the patient needs to stop the drug immediately, and consider the potential harm of the drug to the fetus (see [medication for pregnant women and lactating women]). 4. Lactating women Whether atorvastatin can be secreted from human milk is unknown; However, a small amount of these other drugs can be secreted into milk. Because statins may have potentially serious adverse reactions to newborns receiving lactation, women taking this product are prohibited from lactation (see [medication for pregnant women and lactating women]).

[listing Permit Holder] Pfizer Pharmaceuticals Limited

[packaging unit] box

[main ingredients] The main component of this product is atorvastatin calcium. The chemical name is: EP, - (R ', R')] - 2 - (4-fluorophenyl) B · 6-dihydroxy-5-1-methylethyl-3-phenyl-4 - [(aniline) off] - 1-hydro-pyrrole-1-heptanate calcium trihydrate.

[character] This product is white oval film coated tablets.

[applicable population] adult

[medication for pregnant and lactating women] HMG CoA reductase inhibitor is forbidden in pregnant and lactating women, and the safety of this drug for pregnant women has not been established.

[medication for children] This product should only be used by specialists in children. The treatment experience of this product in children is limited to a few (4 to 17 years old) patients with severe lipid disorders, such as homozygous familial hypercholesterolemia. The recommended starting dose of this product in this patient population is 10mg / day. There is no safety data on the growth and development of this product.

[medication for elderly patients] Of the 39828 patients taking Lipitor in the clinical study, 15813 (40%) were ≥ 65 years old and 2800 (7%) were ≥ 75 years old. There was no difference in overall safety and efficacy between the two populations and young subjects. Other clinical experience reports also showed that there was no difference between the elderly and the young. However, it can not be excluded that some elderly patients are more sensitive to drugs. The elderly (≥ 65 years old) is a susceptibility factor of myopathy. Therefore, the application of Lipitor in the elderly population should be cautious.

[storage] Sealed storage.

Praise degree

zero%

    reminder

    Dear customer:

    In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

    Atorvastatin calcium tablets (Lipitor)

    ¥89.00

    reminder

    To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

    Please enter the correct verification code!
    Loding...
    Can't see clearly. Change one

    Dear customer:

    Your callback failed this time. Please re-enter the verification code to try. Thank you!